NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Major Shareholder Poplar Point Capital Partners Purchases 31,703 Shares

Posted by Chris Copeland on Apr 16th, 2025

NovaBay Pharmaceuticals, Inc. (NYSE:NBY – Get Free Report) major shareholder Poplar Point Capital Partners purchased 31,703 shares of NovaBay Pharmaceuticals stock in a transaction dated Monday, January 27th. The stock was bought at an average price of $0.69 per share, for a total transaction of $21,875.07. Following the completion of the transaction, the insider now directly owns 550,000 shares in the company, valued at $379,500. The trade was a 6.12 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Poplar Point Capital Partners also recently made the following trade(s):

On Friday, January 31st, Poplar Point Capital Partners bought 70,685 shares of NovaBay Pharmaceuticals stock. The stock was bought at an average cost of $0.65 per share, for a total transaction of $45,945.25.
On Thursday, February 20th, Poplar Point Capital Partners bought 1,836 shares of NovaBay Pharmaceuticals stock. The shares were bought at an average price of $0.63 per share, with a total value of $1,156.68.
On Tuesday, February 18th, Poplar Point Capital Partners purchased 3,222 shares of NovaBay Pharmaceuticals stock. The stock was purchased at an average price of $0.66 per share, for a total transaction of $2,126.52.
On Monday, February 3rd, Poplar Point Capital Partners bought 2,597 shares of NovaBay Pharmaceuticals stock. The stock was purchased at an average cost of $0.64 per share, with a total value of $1,662.08.
On Friday, March 7th, Poplar Point Capital Partners bought 102 shares of NovaBay Pharmaceuticals stock. The stock was purchased at an average price of $0.55 per share, for a total transaction of $56.10.
On Tuesday, March 4th, Poplar Point Capital Partners purchased 4,000 shares of NovaBay Pharmaceuticals stock. The stock was purchased at an average cost of $0.58 per share, with a total value of $2,320.00.
On Thursday, February 27th, Poplar Point Capital Partners acquired 385 shares of NovaBay Pharmaceuticals stock. The shares were acquired at an average cost of $0.61 per share, for a total transaction of $234.85.
On Tuesday, February 25th, Poplar Point Capital Partners bought 25,033 shares of NovaBay Pharmaceuticals stock. The stock was acquired at an average cost of $0.62 per share, with a total value of $15,520.46.
On Friday, March 14th, Poplar Point Capital Partners purchased 25,511 shares of NovaBay Pharmaceuticals stock. The stock was acquired at an average price of $0.63 per share, with a total value of $16,071.93.
On Wednesday, March 12th, Poplar Point Capital Partners acquired 11,837 shares of NovaBay Pharmaceuticals stock. The shares were acquired at an average price of $0.62 per share, for a total transaction of $7,338.94.

NovaBay Pharmaceuticals Trading Up 5.4 %

NBY opened at $0.59 on Wednesday. The stock has a market capitalization of $3.43 million, a P/E ratio of -0.01 and a beta of 0.90. NovaBay Pharmaceuticals, Inc. has a 12 month low of $0.36 and a 12 month high of $9.08. The firm’s fifty day simple moving average is $0.60 and its 200 day simple moving average is $0.63.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of NovaBay Pharmaceuticals in a report on Thursday, April 10th. They set a “hold” rating on the stock.

View Our Latest Stock Report on NovaBay Pharmaceuticals

NovaBay Pharmaceuticals Company Profile

(Get Free Report)

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.